-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
Author: Sunshine
On November 3, the CDE official website showed that Merck's cetuximab (trade name: Erbitux) was declared for the market
.
Cetuximab is a human-mouse chimeric IgG1 monoclonal antibody targeting epidermal growth factor receptor (EGFR), and it is also the first anti-EGFR monoclonal antibody approved for marketing in the world
.
It can specifically bind to the EGFR domain expressed on the surface of cancer cells, competitively inhibit the corresponding ligands, block intracellular signal transduction pathways, and thus exert anti-tumor effects; through antibody-dependent cell-mediated cytotoxicity (ADCC) effects Kill tumor cells; down-regulate hypoxia factor 1-α and Bcl2 proto-oncogenes, activate autophagy genes, thereby inducing autophagy by tumor cells
In February 2004, Cetuximab was first launched in the United States, and subsequently launched in the European Union, China, and Japan
.
At present, cetuximab has been approved for marketing in more than 100 countries around the world, mainly for the treatment of colorectal cancer and squamous cell carcinoma of the head and neck (SCCHN)
In September 2021, cetuximab expanded its new indications in the United States, specifically combining encorfenib in the treatment of BRAF V600E mutation-positive metastatic colorectal cancer (CRC) patients who have received previous treatment
.
Cetuximab was originally developed by ImClone, and Merck, BMS and Eli Lilly jointly own the rights
Note: The original text has been deleted
